Kalaris Therapeutics Inc(KLRS)

Biotechnology · Berkeley Heights, NJ

$2.66-0.17 (-6.01%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T21:37:23.397Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:37:23.397Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 58,061,224
TTM free cash flow · period ending 2026-06-30: -45,633,000

FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KLRS Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

KLRS Competitors' Price/FCF Ratio

KLRS

Kalaris Therapeutics Inc

Current

Market Cap

$58.06M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INKT

MiNK Therapeutics, Inc.

vs KLRS

Market Cap

$58.29M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BOLD

Boundless Bio, Inc.

vs KLRS

Market Cap

$57.76M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs KLRS

Market Cap

$58.43M

Price/FCF Ratio

N/A

TTM Avg

98.33

3Y Avg

98.33

5Y Avg

98.33

PDSB

PDS Biotechnology Corporation

vs KLRS

Market Cap

$58.44M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TLPH

Talphera, Inc.

vs KLRS

Market Cap

$57.61M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTB

Connect Biopharma Holdings Limited

vs KLRS

Market Cap

$57.01M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XLO

Xilio Therapeutics, Inc.

vs KLRS

Market Cap

$59.18M

Price/FCF Ratio

N/A

TTM Avg

2.61

3Y Avg

2.61

5Y Avg

2.61

ONCY

Oncolytics Biotech Inc.

vs KLRS

Market Cap

$60.02M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OKYO

OKYO Pharma Limited

vs KLRS

Market Cap

$56.02M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Kalaris Therapeutics Inc (KLRS)	$58.06M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$58.29M	N/A	N/A	N/A	N/A
Boundless Bio, Inc. (BOLD)vs ›	$57.76M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$58.43M	N/A	98.33	98.33	98.33
PDS Biotechnology Corporation (PDSB)vs ›	$58.44M	N/A	N/A	N/A	N/A
Talphera, Inc. (TLPH)vs ›	$57.61M	N/A	N/A	N/A	N/A
Connect Biopharma Holdings Limited (CNTB)vs ›	$57.01M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$59.18M	N/A	2.61	2.61	2.61
Oncolytics Biotech Inc. (ONCY)vs ›	$60.02M	N/A	N/A	N/A	N/A
OKYO Pharma Limited (OKYO)vs ›	$56.02M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

KLRS Price/FCF Ratio Metrics

KLRS Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics